Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 10/2006

01.10.2006 | Clinical Investigation

Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy

verfasst von: Noémi Maár, Erdem Ergun, Alexandra Luksch, Michael Stur

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 10/2006

Einloggen, um Zugang zu erhalten

Abstract

Background

The purpose of this study was to examine the influence of treatment frequency on visual acuity of patients with PDT treatment for subfoveal predominantly classic CNV related to pathological myopia.

Design

Retrospective case series.

Methods

Thirty-seven patients with subfoveal predominantly classic CNV caused by pathologic myopia and treated with PDT were included. All patients received a full ophthalmic examination, including best-corrected visual acuity, slit-lamp biomicroscopy, fundus photography and fluorescein angiography, before first treatment and every 3 months thereafter. Photodynamic therapy was performed according to standard protocol. Main outcome measurements were visual acuity and treatment frequency.

Results

The number of treatments received was 3.35±1.83 (average: 1–7). In 12 eyes (32.43%); the BCVA was stable or increased during the entire follow-up period. In eight eyes (21.62%), the BCVA decreased and did not return to the baseline values. A transient loss of visual acuity (over 3–9 months) with subsequent improvement in visual function was found in 68% (17 eyes). A gain of three or more lines compared with lowest BCVA was found in 56% (14 eyes). The number of treatments did not correlate with baseline BCVA, greatest linear dimension of CNV at baseline or with the change of BCVA from baseline. In cases with transient worsening of BCVA, the recovery of visual acuity correlated significantly with the number of treatments (r=−0.522, P<0.05; Spearman rank correlation) received.

Conclusion

Visual acuity recovery correlates with the number of PDT re-treatments; in many cases, an improvement in visual function after temporary decrease of BCVA can be observed after re-treatment according to current treatment guidelines. The number of PDT treatments has no negative effect on the visual outcome in subfoveal CNVs caused by pathological myopia.
Literatur
1.
Zurück zum Zitat Andrade RE, Farah ME, Costa RA (2003) Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in best disease. Am J Ophthalmol 136:1179–1181PubMedCrossRef Andrade RE, Farah ME, Costa RA (2003) Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in best disease. Am J Ophthalmol 136:1179–1181PubMedCrossRef
2.
Zurück zum Zitat Avila MP, Weiter JJ, Jalkh AE et al (1984) Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91:1573–1581PubMed Avila MP, Weiter JJ, Jalkh AE et al (1984) Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91:1573–1581PubMed
3.
Zurück zum Zitat Axer-Siegel R, Ehrlich R, Weinberger D, Rosenblatt I, Shani L, Yassur Y, Priel E, Kramer M (2004) Photodynamic therapy of subfoveal choroidal neovascularisation in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol 138:602–607PubMedCrossRef Axer-Siegel R, Ehrlich R, Weinberger D, Rosenblatt I, Shani L, Yassur Y, Priel E, Kramer M (2004) Photodynamic therapy of subfoveal choroidal neovascularisation in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol 138:602–607PubMedCrossRef
4.
Zurück zum Zitat Battaglia Parodi M, Da Pozzo S, Ravalico G (2003) Photodynamic therapy for choroidal neovascularization associated with pattern dystrophy. Retina 23:171–176PubMedCrossRef Battaglia Parodi M, Da Pozzo S, Ravalico G (2003) Photodynamic therapy for choroidal neovascularization associated with pattern dystrophy. Retina 23:171–176PubMedCrossRef
5.
Zurück zum Zitat Canakis C, Conway MD, Livir-Rallatos C, Naaman GJ, Ratnakaram R, Men G, Peyman GA (2004) Ocular photodynamic therapy in choroidal neovascularization complicating idiopathic central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 35:168–171PubMed Canakis C, Conway MD, Livir-Rallatos C, Naaman GJ, Ratnakaram R, Men G, Peyman GA (2004) Ocular photodynamic therapy in choroidal neovascularization complicating idiopathic central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 35:168–171PubMed
6.
Zurück zum Zitat Ergun E, Tittl M, Stur M (2004) Photodynamic therapy with verteporfin in subfoveal choroidal neovascularization secondary to central serous chorioretinopathy. Arch Ophthalmol 122:37–41PubMedCrossRef Ergun E, Tittl M, Stur M (2004) Photodynamic therapy with verteporfin in subfoveal choroidal neovascularization secondary to central serous chorioretinopathy. Arch Ophthalmol 122:37–41PubMedCrossRef
7.
Zurück zum Zitat Ergun E, Heinzl H, Stur M (2004) Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularisation in pathologic myopia. Am J Ophthalmol 138:434–438PubMedCrossRef Ergun E, Heinzl H, Stur M (2004) Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularisation in pathologic myopia. Am J Ophthalmol 138:434–438PubMedCrossRef
8.
Zurück zum Zitat Fried M, Siebert A, Meyer-Schwickerath G (1981) A natural history of Fuchs’ spot: a long-term follow-up study. Doc Ophthalmol 28:215–221 Fried M, Siebert A, Meyer-Schwickerath G (1981) A natural history of Fuchs’ spot: a long-term follow-up study. Doc Ophthalmol 28:215–221
9.
Zurück zum Zitat Hampton GR, Kohen D, Bird AC (1983) Visual prognosis of disciform degeneration in myopia. Ophthalmology 90:923–926PubMed Hampton GR, Kohen D, Bird AC (1983) Visual prognosis of disciform degeneration in myopia. Ophthalmology 90:923–926PubMed
10.
Zurück zum Zitat Hollanday JT (1997) Proper method for calculating average visual acuity. J Refract Surg 13:388–391 Hollanday JT (1997) Proper method for calculating average visual acuity. J Refract Surg 13:388–391
11.
Zurück zum Zitat Karacorlu M, Karacorlu S, Ozdemir H, Mat C (2002) Photodynamic therapy with verteporfin for choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol 134:360–366PubMedCrossRef Karacorlu M, Karacorlu S, Ozdemir H, Mat C (2002) Photodynamic therapy with verteporfin for choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol 134:360–366PubMedCrossRef
12.
Zurück zum Zitat Karadimas P, Bouzas EA (2004) Photodynamic therapy with verteporfin for choroidal neovascularization complicating angioid streaks. Ophthalmic Surg Lasers Imaging 35:78–80PubMed Karadimas P, Bouzas EA (2004) Photodynamic therapy with verteporfin for choroidal neovascularization complicating angioid streaks. Ophthalmic Surg Lasers Imaging 35:78–80PubMed
13.
Zurück zum Zitat Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U (2004) Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 138:803–808PubMedCrossRef Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U (2004) Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 138:803–808PubMedCrossRef
14.
Zurück zum Zitat Rogers AH, Greenberg PB, Martidis A, Puliafito CA (2003) Photodynamic therapy of polypoidal choroidal vasculopathy. Ophthalmic Surg Lasers Imaging 34:60–63PubMed Rogers AH, Greenberg PB, Martidis A, Puliafito CA (2003) Photodynamic therapy of polypoidal choroidal vasculopathy. Ophthalmic Surg Lasers Imaging 34:60–63PubMed
15.
Zurück zum Zitat Shanmugam MP, Agarwal M (2005) RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. Ind J Ophthalmol 53:61–63CrossRef Shanmugam MP, Agarwal M (2005) RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. Ind J Ophthalmol 53:61–63CrossRef
16.
Zurück zum Zitat Sickenberg M, Schmidt-Erfurth U, Miller JW, Pournaras CJ, Zografos L, Piguwt B et al (2000) A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularisation in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 118:327–336PubMed Sickenberg M, Schmidt-Erfurth U, Miller JW, Pournaras CJ, Zografos L, Piguwt B et al (2000) A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularisation in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 118:327–336PubMed
17.
Zurück zum Zitat Snyers B, Verougstraete C, Postelmans L, Leys A, Hykin P (2004) Photodynamic therapy of subfoveal neovascular membrane type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 137:812–819PubMedCrossRef Snyers B, Verougstraete C, Postelmans L, Leys A, Hykin P (2004) Photodynamic therapy of subfoveal neovascular membrane type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 137:812–819PubMedCrossRef
18.
Zurück zum Zitat Spaide RF, Donsoff I, Lam DL, Yannuzzi LA, Jampol LM, Slakter J, Sorenson J, Freund KB (2002) Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 22:529–535PubMedCrossRef Spaide RF, Donsoff I, Lam DL, Yannuzzi LA, Jampol LM, Slakter J, Sorenson J, Freund KB (2002) Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 22:529–535PubMedCrossRef
19.
Zurück zum Zitat Spaide RF, Freund KB, Slakter J, Sorenson J, Yannuzzi LA, Fisher Y (2002) Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina 22:545–549PubMedCrossRef Spaide RF, Freund KB, Slakter J, Sorenson J, Yannuzzi LA, Fisher Y (2002) Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina 22:545–549PubMedCrossRef
20.
Zurück zum Zitat Spaide RF, Martin ML, Slakter J, Yannuzzi LA, Sorenson J, Guyer DR, Freund KB (2002) Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin. Am J Ophthalmol 134:62–68PubMedCrossRef Spaide RF, Martin ML, Slakter J, Yannuzzi LA, Sorenson J, Guyer DR, Freund KB (2002) Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin. Am J Ophthalmol 134:62–68PubMedCrossRef
21.
Zurück zum Zitat Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin: one-year results of 2 randomised clinical trials—TAP report 1. Arch Ophthalmol 117:1329–1345 Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin: one-year results of 2 randomised clinical trials—TAP report 1. Arch Ophthalmol 117:1329–1345
22.
Zurück zum Zitat Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin: two-year results of 2 randomised clinical trials—TAP report 2. Arch Ophthalmol 119:198–207 Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin: two-year results of 2 randomised clinical trials—TAP report 2. Arch Ophthalmol 119:198–207
23.
Zurück zum Zitat Verteporfin in Photodynamic Therapy Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularisation in age-related macular degeneration: two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularisation—Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 131:541–560CrossRef Verteporfin in Photodynamic Therapy Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularisation in age-related macular degeneration: two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularisation—Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 131:541–560CrossRef
24.
Zurück zum Zitat Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularisation in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial—VIP report No. 1. Ophthalmology 108:841–852CrossRef Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularisation in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial—VIP report No. 1. Ophthalmology 108:841–852CrossRef
25.
Zurück zum Zitat Verteporfin Roundtable Participants (2005) Guidelines for using Verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 25:112–134CrossRef Verteporfin Roundtable Participants (2005) Guidelines for using Verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 25:112–134CrossRef
26.
Zurück zum Zitat Wachtlin J, Heimann H, Behme T, Foerster MH (2003) Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefe’s Arch Clin Exp Ophthalmol 241:899–906CrossRef Wachtlin J, Heimann H, Behme T, Foerster MH (2003) Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefe’s Arch Clin Exp Ophthalmol 241:899–906CrossRef
27.
Zurück zum Zitat Wachtlin J, Wehner A, Heimann H, Foerster MH (2004) Photodynamische Therapie mit Verteporfin bei Patienten mit idiopathischer chorioidaler Neovaskularisation. 2-Jahres-Ergebnisse. Ophthalmologe 101:489–495PubMedCrossRef Wachtlin J, Wehner A, Heimann H, Foerster MH (2004) Photodynamische Therapie mit Verteporfin bei Patienten mit idiopathischer chorioidaler Neovaskularisation. 2-Jahres-Ergebnisse. Ophthalmologe 101:489–495PubMedCrossRef
Metadaten
Titel
Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy
verfasst von
Noémi Maár
Erdem Ergun
Alexandra Luksch
Michael Stur
Publikationsdatum
01.10.2006
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 10/2006
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-005-0246-6

Weitere Artikel der Ausgabe 10/2006

Graefe's Archive for Clinical and Experimental Ophthalmology 10/2006 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.